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Letters to the Editor
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Multiple Myeloma
Analysis of the efficacy and toxicity of
bortezomib for treatment of relapsed or refractory
multiple myeloma in community practice
The clinical data on the efficacy and toxicity of
bortezomib as treatment for multiple myeloma
patients are restricted to prospective phase II stud-
ies in expert myeloma centers. Here we report a
multi-institutional analysis of the efficacy and tox-
icity of bortezomib in patients with relapsed or
refractory multiple myeloma who were treated in




Between November 2002 and December 2004, 50
patients with relapsed or refractory multiple myeloma
were treated with bortezomib in centers in the
Netherlands. The clinical data of these patients were
obtained by means of case research. The mean age of the
patients was 59 years (range 37–87); 33 patients had IgG,
10 patients IgA, 6 patients light-chain and 1 patient non-
secretory myeloma. The median number of prior treat-
ments was 3 (range 1-5). Twenty-nine patients were treat-
ed with high-dose melphalan with autologous stem cell
support and 8 patients had received an allogeneic stem cell
transplant. 
Patients treated in the compassionate need program
received up to eight 3-weekly cycles of bortezomib.
Within each cycle, bortezomib 1.3 mg/m2 was adminis-
tered as an intravenous bolus twice weekly on days 1, 4,
8 and 11. Treatment was withheld in case of any grade ≥3
non-hematologic toxicity or grade 4 hematologic toxicity
considered to be drug-related. Treatment was resumed at
a dose of 1.0 mg/m2 after resolution of the non-hemato-
logic toxicity to grade 2 or better and for hematological
toxicity to an absolute neutrophil count ≥0.5¥109/L and
platelet count ≥20¥109/L. Responses were evaluated
based on the EBMT criteria.1 NCI Toxicity Criteria (ver-
sion 2.0) were used to grade the non-hematologic toxicity.
At the time of analysis, 33 patients (66%) were still alive.
The median follow-up from the start of bortezomib treat-
ment was 7 months (range 2-26 months). A clinical
response was observed in 23 patients (46%), including
complete response in 2 patients, partial response in 15 and
minimal response in 6 patients. The median time to
response was 6 weeks and the median duration of
response was 9 months. The median progression-free sur-
vival was 7 months and the median overall survival was
15 months. (Figure 1). Response to bortezomib occurred
in 5 of the 15 patients with a complete or partial deletion
of chromosome 13. 
Univariate and multivariate analyses of variables such as
number of prior treatment regimens, treatment with
thalidomide or dexamethasone, abnormalities of chromo-
some 13, serum b2 microglobulin and serum albumin lev-
els did not show any statistically significant differences in
progression-free survival and overall survival. This could
be partly due to the small sample size involved. Seven
patients who had no response after two treatment cycles
of bortezomib alone continued treatment and received
oral dexamethasone (20 mg) on the day of and the day fol-
lowing each bortezomib dose. One of these patients, who
was previously refractory to corticosteroids, had an addi-
tional response on the combination therapy. Further
investigations into the possibility of synergy between
Figure 1. Overall survival and progression-free survival.
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bortezomib and dexamethasone are warranted.2,3 The
most common toxicities were gastrointestinal symptoms,
thrombocytopenia, neutropenia, fatigue and peripheral
neuropathy (Figure 2). The majority of the side effects
were low grade. The thrombocytopenia was transient,
with recovery within the 10-day rest period in each cycle,
and was not associated with bleeding complications. Six
patients had herpes zoster. The dose of bortezomib was
reduced in 18 patients and the drug was discontinued in
12 patients because of side effects: peripheral neuropathy
(n=6), gastrointestinal symptoms (n=4), skin rash (n=1)
and orthostatic hypotension (n=1). 
In our observational analysis, the response rate to borte-
zomib was comparable to those in two prospective clini-
cal studies, CREST and SUMMIT, which reported
response rates of 35-50%.4,5 The median duration of
response was 9 months. In the CREST study, the median
duration of response was 9.5 months and 13.7 months in
the 1.0 mg/m2 and 1.3 mg/m2 groups, respectively, while
in the SUMMIT study the median response duration was
12 months. A possible explanation for the shorter dura-
tion of response in our series may be that dose reduction
was performed more frequently by local physicians in our
study than in CREST and SUMMIT, which were conduct-
ed in expert myeloma centers. Therefore, the clinical prac-
tice in community hospitals of reducing doses in patients
with treatment-related toxicity without adherence to
well-defined guidelines may jeopardize the outcome of
the efficacy of bortezomib in multiple myeloma. 
A remarkable observation in our series was the high
incidence of herpes zoster. Six patients developed a herpes
zoster infection during treatment with bortezomib. The
transcription factor NF-kB has been demonstrated to play
a pivotal role in cytokine signaling and the generation of
cell-mediated immune response in numerous models.6,7
Therefore, inhibition of NF-kB may increase the risk of
reactivation of the varicella zoster virus. Prophylactic
antiviral medication should be considered in predisposed
patients who receive bortezomib.
In conclusion, bortezomib can induce marked and
durable response in advanced multiple myeloma. Overall,
bortezomib was well tolerated and the toxicity was
acceptable.
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Disorders of Hemostasis
Exon skipping partially restores  factor VIII
coagulant activity in patients with mild
hemophilia A with exon 13 duplication
Ectopic mRNA was analyzed by reverse tran-
scriptase polymerase chain reaction (RT-PCR) in
patients with duplication of F8 gene exon 13, a
mutation which has been demonstrated to be a
cause of mild hemophilia A in 32% of Northern
Italian subjects. Two different transcripts originate
from mutated genomic DNA, due to alternative
splice processes. The larger-sized transcript con-
tains both duplicated exons 13, the smaller one
contains only one exon 13. The residual FVIII:C
activity which accounts for the mild hemophilia A
phenotype derives from the latter transcript.
haematologica 2005; 90:997-999
(http://www.haematologica.org/journal/2005/7/997.html)
We described the duplication of exon 13 as a disease
causative mutation in a cohort of Northern Italian
patients with hemophilia A (HA).1 The association of the
alteration with a residual FVIII coagulant activity >8%
suggested that a certain amount of normal protein was
being produced. We could, therefore, hypothesize: (i)
that an elongated form of mRNA is generated and that it
somehow ends up in the translation of a partially func-
tioning normal protein; or (ii) that alternative splicing
processes produce two forms of RNA , but that only one
of them is able to translate a correct protein. 
To verify these working hypotheses,  we  undertook a
study on ectopic mRNA obtained from  the only available
tissue, peripheral blood. mRNA was obtained from the
lymphocytes of 6/10 patients and from 40 healthy con-
trols, following informed consent. cDNA, reverse tran-
scribed (Reverse Transcription kit - Clontech, Palo Alto,
